Minomic is an immuno-oncology company developing “next-gen” cancer testing and immuno-therapeutics for global markets. R&D Capital Partners’ understanding of our research activities avoided any delays in implementing their innovative loan package. With their financial support in place we were able to undertake our various pilot trials in the US and are able to progress our planned human therapeutic trials utilising our proprietary technology. The data from these trials has strengthened our intellectual property which, in turn, underpins our ability to raise new equity. This new equity together with further loans from R&DCP will be used to commercialise our diagnostic test and fund further therapeutic development.
David Burdis – Chief Operations and Financial Officer